/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Top Line
  2. How we picked the Fierce 15
How we picked the Fierce 15

How we picked the Fierce 15

The Top Line · Oct 9, 2026

Fierce Biotech editors reveal how they selected the Fierce 15, highlighting lean operations, bold targets, and high-impact innovation.

Biotech Startups Conceal Pipeline Targets to Prevent Fast Followers from Overtaking Development

Biotech startups are increasingly keeping their secondary pipeline assets and specific biological targets confidential. With heightened market competition, early disclosure risks letting fast-following rivals glean scientific insights and outpace the originator during clinical trials.

How we picked the Fierce 15 thumbnail

How we picked the Fierce 15

The Top Line·a month ago

Early-Stage Biotechs Take Big Swings on Difficult Targets Abandoned by Big Pharma

Emerging startups are actively targeting high-risk biological mechanisms that large pharmaceutical corporations failed to drug or dropped in trials. Companies like Sirenax and Beacon Therapeutics intentionally tackle hurdles like SARM-1 and ocular gene therapies where prior pharma programs stumbled.

How we picked the Fierce 15 thumbnail

How we picked the Fierce 15

The Top Line·a month ago

Particle Accelerators Decentralize Radiopharmaceutical Isotope Sourcing for Lean Biotech Operations

Radiopharmaceutical development historically required navigating intricate nuclear reactor supply chains. Adopting particle accelerators instead allows early-stage companies to source isotopes with leaner teams and smaller facility footprints, streamlining scalable manufacturing.

How we picked the Fierce 15 thumbnail

How we picked the Fierce 15

The Top Line·a month ago

Screening Human B Cells Leverages Evolution Over Purely Computational Antibody Design

Despite widespread industry hype around in silico antibody generation, screening exposed human B cells captures natural structural diversity that algorithms miss. Platforms focusing on human biology rely on evolutionary optimization to uncover functional antibodies for hard-to-drug targets.

How we picked the Fierce 15 thumbnail

How we picked the Fierce 15

The Top Line·a month ago

Diagnostic Testing for Fertility Dysbiosis Lacks Corresponding Therapeutic Interventions

Reproductive medicine suffers from a distinct clinical disconnect where diagnostics can confirm microbiome dysbiosis, but clinicians have no approved drugs to treat it. This creates substantial opportunities for biotechs developing targeted assets to regulate bacterial environments during IVF implantation.

How we picked the Fierce 15 thumbnail

How we picked the Fierce 15

The Top Line·a month ago